Vaccines
The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine for children ages 5 to 11.
In the face of Delta, the actual efficacy of the vaccines has come into question, while global cases and deaths from COVID-19 increased for the first time in two months, primarily in Europe.
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA’s signal to start shipping the vaccines.
A large number of people were waiting for the breast cancer vaccine. Now, at present, the world has witnessed the first potential vaccine. Let’s take a look at it.
On Tuesday morning, Provention Bio announced positive interim results from its Phase I PROVENT study of PRV-101.
In documents prepared for the meeting, the vaccine demonstrated 90.7% effectiveness for the children in this age group.
BioNTech plans to increase its manufacturing capacity in Africa over time through the supplementation of new manufacturing lines and construction of additional manufacturing sites.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.
Initial results showed a strong neutralizing antibody response and favorable safety profile among the participants.
PRESS RELEASES